SOLARA Q4 FY26 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Solara Active Pharma Sciences reported its best quarter in 8 quarters (Q4 FY26), with revenue of INR 392 cr (+12% QoQ), gross margin 47% (+170 bps QoQ), and EBITDA of INR 61 cr (+65% QoQ). The base business (ex-ibuprofen) continues to drive performance with 26% EBITDA margins. The ibuprofen business remains a drag with negative EBITDA, and management has appointed bankers to evaluate strategic options (sale or conversion) with decision expected in H1 FY27. The company reduced debt by INR 158 cr in FY26 and targets debt-free status by FY29. R&D is being revived with plans for 4-5 DMF filings per year, though benefits are expected from FY29 onwards. No explicit forward guidance was given, but management expressed confidence in maintaining momentum.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong Q4 performance (12% QoQ revenue growth, 65% QoQ EBITDA growth), highlighted the base business's superior profitability (26% EBITDA margin), and outlined clear strategic priorities including evaluating options for the loss-making ibuprofen business. The tone was co
- Q&A Session: Neutral — Analysts pressed on the sustainability of the Q4 momentum, the strategic options for ibuprofen, the lack of R&D output, and the outlook for the subscale CRAMS business. Management's responses were detailed but included cautions on the ibuprofen timeline and acknowledged that R&D benefits will only m
Revenue Growth Drivers
- Strong base business momentum with healthy order book and customer engagement
- Debottlenecking and capacity optimization for high-margin products
- Ibuprofen business continues to be a drag with negative EBITDA
Growth vs Margin Focus
Management emphasized driving revenue growth through base business expansion (new customers, geographies) while simultaneously improving margins through operational efficiency, yield improvement, and capacity debottlenecking. The target is to deliver sustainable, profitable growth as stated in their
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited (SOLARA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.